Emerging Cancer Therapies: Immunotherapy, Gene Editing & More
CAR T-cells, checkpoint inhibitors, CRISPR, tumor treating fields — the therapies redefining what is curable, from Chapter 4 of F*CK CANCER.
There is a class of cancer treatment that would have sounded like science fiction a generation ago: reprogram a patient's own immune cells into guided missiles. Edit the faulty genes that started the cancer. Aim viruses that hunt tumor cells and leave healthy ones alone. Chapter 4 of the book maps this territory — the therapies that are redefining what "curable" means.
Unleashing the immune system
Cancer's most dangerous talent is not growth — it is camouflage. Tumors display false "don't shoot" signals that switch off the immune cells sent to kill them. Checkpoint inhibitors like Pembrolizumab jam those signals, releasing brakes on immune cells that already know how to fight. The results in the right tumors can be extraordinary: in studies of Dostarlimab for a genetically specific form of rectal cancer, every patient in an early trial cohort saw their tumor disappear — no surgery, no radiation, no chemotherapy.
Then there are the living drugs. CAR T-Cell Therapy removes a patient's T-cells, genetically engineers them to recognize their cancer, multiplies them into the hundreds of millions, and infuses them back — producing remissions in blood cancers that had exhausted every other option. TIL Therapy takes a different route: harvest the immune cells already inside the tumor, grow them into an overwhelming army in the lab, and send them home. And Oncolytic Viruses — engineered viruses that infect cancer cells until they burst — both kill directly and splatter tumor antigens across the battlefield, waking the wider immune system.
Precision beyond the immune system
Chapter 4 ranges well past immunotherapy:
- Targeted drugs like Gleevec — the molecule that turned a fatal leukemia into a manageable condition — and Enhertu, an antibody-drug conjugate that ferries chemotherapy directly into HER2-positive cancer cells
- CRISPR Gene Editing — the molecular scissors that can cut faulty cancer-driving genes at the source
- Advanced radiation — proton therapy and precision techniques that bend the dose around healthy tissue
- Physical energy therapies — Tumor Treating Fields that disrupt cell division with electric fields, hyperthermia, cryoablation, and pulsed electric fields
The question is no longer whether the body can beat cancer. It is whether we can remove what stops it.
How to use this map
No single chapter can tell you which therapy fits your case — that depends on your tumor's type, genetics, and stage. What this chapter gives you is the landscape and the vocabulary: what each therapy is, who it tends to help, what it costs in side effects, and what to ask your oncology team. Every one of the therapies above is profiled with evidence status in the free Cure Finder — search it before your next appointment, and walk in with questions that matter.
The complete profiles — mechanisms, trial results, risks, and the questions to bring to your medical team — fill the largest chapter of the book. It was written so that "there's nothing more we can do" is met with: have we checked everything?
Educational content, not medical advice. Eligibility for these therapies depends on tumor genetics, cancer type, and clinical factors — decisions belong with your oncology team.
Frequently asked questions
What is CAR T-cell therapy?
CAR T-cell therapy removes a patient’s own immune cells, engineers them in a lab to recognize cancer markers, and reinfuses them as living drugs. It has produced complete remissions in certain blood cancers that resisted everything else.
What made dostarlimab famous?
In a small 2022 trial at Memorial Sloan Kettering, every rectal cancer patient with mismatch-repair-deficient tumors treated with dostarlimab had a complete remission — no surgery, radiation, or chemotherapy needed. Larger trials are working to confirm the result.
Why doesn’t immunotherapy work for everyone?
Immunotherapy works best in tumors with many mutations or specific markers like high MSI or PD-L1 expression. So-called cold tumors that hide from immune detection often resist, which is why biomarker testing before treatment matters so much.